Kanitinib
- Generic Name
- Kanitinib
A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT04093466
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Kanitinib in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT02916095
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath